Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 16, No. 2, 2007
Issue release date: February 2007
Section title: Original Paper
Open Access Gateway
Med Princ Pract 2007;16:137–141

Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia

Yılmaz N.a · Herken H.b · Cicek H.K.a · Celik A.a · Yürekli M.c · Akyol Ö.d
Departments of aBiochemistry and Clinical Biochemistry and bPsychiatric Disorders, Faculty of Medicine, University of Gaziantep, Gaziantep, cDepartment of Molecular Biology, Faculty of Science and Art, University of Inonu, Malatya, and dDepartment of Biochemistry and Clinical Biochemistry, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
email Corresponding Author

Prof. Dr. Necat Yılmaz

Department of Biochemistry and Clinical Chemistry, Faculty of Medicine

University of Gaziantep

TR–27310 Gaziantep (Turkey)

Tel. +90 342 360 1200, Fax +90 342 360 1617, E-Mail nyilmaz@gantep.edu.tr


  1. Ritsner M, Maayan R, Gibel A, Strous RD, Modai I, Weizman A: Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 2004;14:267–273.
  2. Binello E, Gordon CM: Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 2003;3:635–641.
  3. Strous RD, Maayan R, Lapidus R, Goredetsky L, Zeldich E, Kotler M, Weizman A: Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res 2004;71:427–434.
  4. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T: Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 2002;58:69–74.
  5. Walsh P, Spelman L, Sharifi N, Thakore JH: Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005;30:431–437.
  6. Zoroglu SS, Yurekli M, Meram I, Sogut S, Tutkun H, Yetkin O, Sivasli E, Savas HA, Yanik M, Herken H, Akyol O: Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct 2003;21:55–60.
  7. Zoroglu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, Akyol O: The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002;36:309–315.
  8. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–267.
  9. Huang CH, Chen ML, Tsai YL, Tsai MT, Chen CH: Elevated adrenomedullin mRNA in lymphoblastoid cells from schizophrenic patients. Neuroreport 2004;15:1443–1446.
  10. Jansen LM, Gispen-de Wied CC, Gademan PJ, De Jonge RC, van der Linden JA, Kahn RS: Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophr Res 1998;33:87–94.
  11. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B: Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab 1998;83:3130–3133.
  12. Boudarane M, Legros JJ: Study of the stress response: role of anxiety, cortisol and DHEAS. Encéphale 2002;28:139–146.
  13. Akwa Y, Baulieu EE: Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Curr Opin Endocrinol Diabetes 2000;7:160–167.
  14. Lerer B, Ran A, Blacker M, Silver H, Weller M, Drummer D, Ebstein B: Neuroendocrine responses in chronic schizophrenia. Schizophr Res 1988;1:405–410.
  15. Muck-Seler D, Pivac D, Jakovljevic M, Brzovic Z: Platelet serotonin, plasma cortisol, and dexamethasone supression test in schizophrenic patients. Biol Psychiatry 1999;45:1433–1439.
  16. Walder DJ, Walker EF, Lewine RJ: Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2000;48;1121–1132.
  17. Roy A, Pickar D, Doran A, Wolkowitz O, Gallucci W, Chrousos G: The corticotropin-releasing hormone stimulation tests in chronic schizophrenia. Am J Psychiatry 1986;143:1393–1397.
  18. Holsboer F: Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001;62:77–91.
  19. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995–1005.
  20. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai B: Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998;83:867–875.
  21. Dawson VL, Dawson TM: Nitric oxide actions in neurochemistry. Neurochem Int 1996;29:97–111.
  22. Herken H, Uz E, Ozyurt H, Akyol O: Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 2001;52:289–290.
  23. Richards AM, Nichoils MG, Lewis L, Lainch-Bury JG: Adrenomedullin. Clin Sci 1996;91:3–16.
  24. Shan J, Krukoff TL: Distribution of preproadrenomedullin mRNA in the rat central nervous system and its modulation by physiological stressors. J Comp Neurol 2001;26:88–100.
    External Resources
  25. Henning U, Krieger K, Loeffler S, Rivas F, Orozco G, Manuel G: Increased levels of glucocorticoid receptors and enhanced glucocorticoid receptor auto-regulation after hydrocortisone challenge in B-lymphoblastoids from patients with affective disorders. Psychoneuroendocrinology 2005;30:325–332.
  26. Ritsner M, Gibel M, Maayan A, Ratner Y, Ram E, Biadsy H, Modai I, Weizman A: Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 2005;30:1913–1922.
  27. Mann K, Rossbach W, Muller MJ, Muller-Siecheneder F, Pott T, Linde I: Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006;31:256–264.